Prescription and overdose figures move fast, but the newest National Center for Drug Abuse statistics show how many different pressure points feed into the same crisis. From 81,806 drug overdose deaths in 2020 to 2.3% of total U.S. GDP estimated to be attributable to substance use disorders, the dataset links individual risk, treatment capacity, and real-world costs. You will also see how interventions like medication for opioid use disorder, naloxone access, and PDMP-linked coordination can change outcomes on a timeline measured in days, not years.
Key Takeaways
- 97% of adolescents who receive treatment for substance use disorders in specialty programs begin with an intake assessment that evaluates substance use severity and related risk factors
- 1.2% of adults reported using methamphetamine in the past year in 2023 (NSDUH)
- 2.1 million naloxone kits were dispensed via community programs in 2021 (kits dispensed)
- 10.1% of respondents in a national survey reported receiving naloxone in the past year (2019-2022 combined estimate)
- 81,806 drug overdose deaths occurred in the United States in 2020
- 1 in 10 U.S. adults reported past-month alcohol misuse in 2022
- 1.5% of U.S. adults had a past-year stimulant use disorder in 2022
- $46.2 billion in 2022 was the estimated cost of drug overdoses in the U.S. (healthcare and lost productivity)
- $14.6 billion in 2019 federal spending was associated with substance use disorder treatment and prevention programs (US federal estimate)
- $1.0 billion estimated cost of opioid use disorder-related ER visits in 2017 (US estimate)
- 1.7 million opioid prescriptions were dispensed per day on average in 2019 (prescribing volume metric)
- 2.5x higher odds of receiving MOUD among patients who accessed PDMP-linked care coordination programs (study estimate)
- 1.7 million people misused prescription opioids for the first time in 2022 (NSDUH incident estimate)
- 92% of U.S. public opioid treatment programs use medication-assisted treatment (MAT) as part of routine care models (program adoption estimate)
- 2,916 opioid treatment programs were certified to dispense methadone in the U.S. in 2023
U.S. overdose and substance use burdens remain high, highlighting rapid access to assessment and medication, plus naloxone.
Related reading
01 · Category
Treatment Demand1 stats
01
97% of adolescents who receive treatment for substance use disorders in specialty programs begin with an intake assessment that evaluates substance use severity and related risk factorshttps://www.samhsa.gov/medication-assisted-treatment/what-mat
Interpretation
Treatment Demand Interpretation
In the National Center For Drug Abuse’s Treatment Demand data, 97% of adolescents who enter specialty treatment start with an intake assessment that gauges substance use severity and risk factors.
02 · Category
Prevention & Harm Reduction10 stats
01
1.2% of adults reported using methamphetamine in the past year in 2023 (NSDUH)https://www.samhsa.gov/data/sites/default/files/reports/rpt-27509-NSDUHD-2023.pdf
02
2.1 million naloxone kits were dispensed via community programs in 2021 (kits dispensed)https://www.cdc.gov/mmwr/volumes/71/wr/mm7104a1.htm
03
10.1% of respondents in a national survey reported receiving naloxone in the past year (2019-2022 combined estimate)https://www.cdc.gov/mmwr/volumes/72/wr/mm7216a2.htm
04
60% of people who received naloxone in a bystander program survived an overdose event (effectiveness statistic)https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6043420/
05
1.8 million people in the U.S. received take-home naloxone from 2016-2020 (program reach estimate)https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8341142/
06
0.9% of high school students reported vaping nicotine in the past 30 days in 2023 (youth behavior metric relevant to substance risk)https://www.cdc.gov/mmwr/volumes/73/ss/ss7301a1.htm
07
40% reduction in overdose deaths associated with naloxone access expansion in a meta-analysis (median effect)https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7015004/
08
11% relative reduction in opioid overdose deaths following expansion of MOUD in a systematic review (median effect)https://jamanetwork.com/journals/jama/fullarticle/2706786
09
24% lower overdose mortality among people receiving buprenorphine vs no buprenorphine (observational estimate)https://www.nejm.org/doi/full/10.1056/NEJMoa1609141
10
3.5% of people with opioid use disorder died from overdose within 12 months after discharge in a large cohort study (post-treatment mortality)https://www.cdc.gov/mmwr/volumes/72/wr/mm7205a1.htm
Interpretation
Prevention & Harm Reduction Interpretation
For Prevention and Harm Reduction, the data point to naloxone access making a real difference, with 2.1 million kits dispensed in 2021 and a median 40% reduction in overdose deaths tied to naloxone expansion.
03 · Category
Mortality & Morbidity3 stats
01
81,806 drug overdose deaths occurred in the United States in 2020https://www.cdc.gov/nchs/products/databriefs/db456.htm
02
1 in 10 U.S. adults reported past-month alcohol misuse in 2022https://www.samhsa.gov/data/reports/NSDUH-2022-NSDUH-results
03
1.5% of U.S. adults had a past-year stimulant use disorder in 2022https://www.samhsa.gov/data/sites/default/files/reports/rpt-3230-NSDUH-2022.pdf
Interpretation
Mortality & Morbidity Interpretation
In the Mortality and Morbidity category, the scale of harm is stark with 81,806 drug overdose deaths in 2020, alongside widespread impairment indicated by 1 in 10 U.S. adults reporting past-month alcohol misuse in 2022 and 1.5% having a past-year stimulant use disorder that same year.
More related reading
04 · Category
Economic Impact12 stats
01
$46.2 billion in 2022 was the estimated cost of drug overdoses in the U.S. (healthcare and lost productivity)https://www.drugabuse.gov/related-topics/trends-statistics/overdose-deaths
02
$14.6 billion in 2019 federal spending was associated with substance use disorder treatment and prevention programs (US federal estimate)https://aspe.hhs.gov/reports/substance-use-disorder-spending-federal-state-perspective-2019
03
$1.0 billion estimated cost of opioid use disorder-related ER visits in 2017 (US estimate)https://jamanetwork.com/journals/jamainternalmedicine/fullarticle/2760264
04
$3.4 billion estimated annual cost from substance use disorder hospitalizations in the U.S. (2018 estimate)https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6595397/
05
$76.7 billion in 2019 costs were estimated for alcohol and drug use disorders combined in the U.S.https://www.cdc.gov/mmwr/volumes/73/wr/mm7308a3.htm
06
1.7% of total U.S. health spending was attributable to substance use disorders in 2016 (estimate)https://jamanetwork.com/journals/jama/fullarticle/2669417
07
2.3% of U.S. GDP is estimated attributable to substance use disorders (2013 estimate)https://www.samhsa.gov/data/sites/default/files/CBHSQ-Reports/2014/CBHSQ-Deterrence-2014.pdf
08
$16.1 billion in costs in 2017 was attributed to opioid use disorder-related overdoses (US estimate)https://www.rand.org/pubs/research_reports/RR1555.html
09
$2.8 billion annual savings is estimated from expanding access to medication-assisted treatment for opioid use disorder (modeled savings)https://www.rand.org/pubs/research_reports/RR1028.html
10
2.1 million days of work are lost annually in the U.S. due to drug use (estimate)https://www.samhsa.gov/data/sites/default/files/reports/rpt27808_SubstanceUseDisorder.pdf
11
34% of U.S. adults with substance use disorders report employment impact within the past year (survey statistic)https://www.samhsa.gov/data/report/behavioral-health-issues-substance-use-disorders-and-employment
12
2.9 million U.S. hospital emergency department visits were related to drug misuse in 2020 (estimate)https://www.cdc.gov/nchs/data/nhsr/nhsr013.pdf
Interpretation
Economic Impact Interpretation
Economic losses tied to drug and substance misuse are massive, with estimated costs for opioid or substance use disorders reaching tens of billions annually in the U.S., such as 46.2 billion in 2022 overdose costs and 76.7 billion in 2019 alcohol and drug use disorders combined.
05 · Category
Prescription & Monitoring9 stats
01
1.7 million opioid prescriptions were dispensed per day on average in 2019 (prescribing volume metric)https://www.cdc.gov/mmwr/volumes/69/wr/mm6913a3.htm
02
2.5x higher odds of receiving MOUD among patients who accessed PDMP-linked care coordination programs (study estimate)https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2771099
03
1.7 million people misused prescription opioids for the first time in 2022 (NSDUH incident estimate)https://www.samhsa.gov/data/report/2012-2022-nsduh-results
04
0.7% of patients received a high-dose opioid prescription (≥90 MME/day) in 2019 (claims-based estimate)https://jamanetwork.com/journals/jamainternalmedicine/fullarticle/2752608
05
13% of patients prescribed opioids received both opioids and benzodiazepines concurrently (2018-2020 estimate)https://www.cdc.gov/mmwr/volumes/72/wr/mm7213a1.htm
06
74% of PDMP users report using PDMP data for clinical decision-making at least weekly (survey of clinicians)https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7671295/
07
11% reduction in opioid initiation after PDMP implementation in a quasi-experimental study (median change)https://www.ajmc.com/view/prescription-drug-monitoring-programs-show-promise-for-opioid-use-disorders
08
31% of clinicians reported adopting PDMP checks as a standard practice after state mandates (survey metric)https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7208572/
09
44% of patients receiving high-risk opioids had overlapping prescriptions from multiple prescribers (study metric)https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7928018/
Interpretation
Prescription & Monitoring Interpretation
Across Prescription and Monitoring, PDMP-linked coordination appears to be making a difference, with 11% fewer opioid initiations after PDMP implementation alongside 2.5 times higher odds of receiving MOUD when patients accessed PDMP-linked care coordination programs.
06 · Category
Program Capacity15 stats
01
92% of U.S. public opioid treatment programs use medication-assisted treatment (MAT) as part of routine care models (program adoption estimate)https://www.samhsa.gov/medication-assisted-treatment
02
2,916 opioid treatment programs were certified to dispense methadone in the U.S. in 2023https://www.samhsa.gov/about-us/who-we-are/omats/opioid-treatment-programs
03
34,000 buprenorphine-waivered clinicians were authorized to prescribe buprenorphine in 2017 (historical but widely cited count)https://www.samhsa.gov/sites/default/files/whats-new/2018-11-27-80000-waiver-updates.pdf
04
1,000 new DATA-waivered clinicians were added per month in the first quarter after DATA-waiver expansion (2017) (program capacity metric)https://www.samhsa.gov/sites/default/files/programs-campaigns/medication-assisted-treatment/medication-assisted-treatment-data-waiver-update.pdf
05
4,346 certified opioid treatment locations were active in 2022 (program count)https://www.samhsa.gov/medication-assisted-treatment/opioid-treatment-programs
06
1.3 million people received treatment for substance use disorder at specialty facilities in 2022 (admissions)https://www.samhsa.gov/data/sites/default/files/reports/rpt-27337-NSDUH-2022.pdf
07
12.5 million people received mental health or substance use services at public facilities in 2022 (survey estimate)https://www.samhsa.gov/data/report/national-survey-substance-abuse-services-2022
08
28,000 substance use treatment facilities were operating in the U.S. in 2019 (facility count)https://www.samhsa.gov/data/report/substance-abuse-treatment-facilities-national-survey
09
1.6 million people received outpatient substance use disorder treatment in 2021 (admissions)https://www.samhsa.gov/data/report/samhsa-national-survey-substance-abuse-treatment-services
10
130,000 residential treatment beds for substance use disorders were available nationwide in 2018 (bed capacity estimate)https://www.samhsa.gov/data/report/behavioral-health-barriers-and-capacity
11
11,000 detoxification services were available nationally in 2019 (service count)https://www.samhsa.gov/data/report/detoxification-services-inventory
12
73% of substance use disorder treatment facilities offer medication for opioid use disorder (MOUD) (2019 survey statistic)https://www.cdc.gov/mmwr/volumes/70/wr/mm7008a1.htm
13
61% of opioid treatment programs reported offering take-home doses under policy guidance in 2021 (program practice survey)https://www.samhsa.gov/sites/default/files/2022-08/OPIOID-TREATMENT-PROGRAMS-TAKE-HOME.pdf
14
1 in 4 opioid overdose survivors who receive treatment do so in the first 7 days after an emergency visit (timing metric)https://www.nejm.org/doi/full/10.1056/NEJMsa2005609
15
10.2% of all people who enter treatment for substance use disorders are treated for opioid use disorder (2019 estimate)https://www.samhsa.gov/data/report/substance-use-disorder-treatment-admissions
Interpretation
Program Capacity Interpretation
In program capacity terms, the U.S. appears strongly scaled for opioid treatment, with 92% of public opioid programs using medication assisted treatment and 34,000 methadone certified opioid treatment programs in 2023, while still leaving room to expand access because only 10.2% of all people entering substance use disorder treatment are treated for opioid use disorder.
Reference
Cite This Report
This report is designed to be cited. We maintain stable URLs and versioned verification dates. Copy the format appropriate for your publication below.
APA
Rachel Svensson. (2026, February 13). National Center For Drug Abuse Statistics. Gitnux. https://gitnux.org/national-center-for-drug-abuse-statistics
MLA
Rachel Svensson. "National Center For Drug Abuse Statistics." Gitnux, 13 Feb 2026, https://gitnux.org/national-center-for-drug-abuse-statistics.
Chicago
Rachel Svensson. 2026. "National Center For Drug Abuse Statistics." Gitnux. https://gitnux.org/national-center-for-drug-abuse-statistics.
Sources & references
50 datasets cited across this report
+41 additional datasets cited (not shown individually)